Lanabecestat
As of the edition of 20 October 2026, Lanabecestat is a small molecule: stopped in 2019; acts on BACE1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2019
- Kind
- Small molecule
- Registered trials
- 19, 6 stopped early
- Disease areas
- Mental health; Nervous system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Lanabecestat.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BACE1 | Beta-secretase 1 | P56817 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 16 | 13 | 0 | 3 |
| Phase 3 | 3 | 0 | 0 | 3 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2012 to now |
| Eli Lilly | Lead sponsor of trials | 2018 to now |